Mark Cuban's Cost Plus to develop US-made ibogaine

Mark Cuban's Cost Plus Drugs is set to embark on a new venture to develop ibogaine domestically in the United States, in collaboration with the Department of Health and Human Services (HHS). This initiative aims to bolster the availability of ibogaine, a psychoactive compound under investigation for its potential in treating opioid use disorder and other conditions.

Cost Plus and HHS collaboration

The partnership between Cost Plus Drugs and HHS represents a significant step towards establishing a U.S.-based production line for ibogaine. This move is expected to address supply chain challenges and ensure a more reliable supply of the compound for research and potential therapeutic use.

Why it matters

Ibogaine has been gaining attention for its potential to treat opioid addiction, an area of critical need given the ongoing opioid crisis. By developing a domestic source of ibogaine, Cost Plus Drugs and HHS aim to facilitate research and potentially expedite the availability of new treatment options.

This collaboration highlights the growing interest in alternative therapies for addiction and mental health disorders, and the role of public-private partnerships in advancing medical research and innovation.

The initiative underscores the importance of developing domestic capabilities for producing promising therapeutic compounds, reducing dependency on international sources, and enhancing the resilience of the healthcare supply chain.